# Formosa Pharmaceuticals, Inc.

*biotech · news · 2026-05-21 · The Manila Times*

## Key points

- TSY-310 is a bispecific ADC targeting both EGFR and ROR1 in solid tumors.
- Preclinical results show TSY-310 induces a strong bystander effect, killing antigen-negative nearby tumor cells.
- The ADC exhibits enhanced lysosomal trafficking in tumor cells, ensuring efficient cytotoxic payload release.
- TSY-310 will be presented at ASCO 2026, highlighting its selectivity and efficacy in heterogeneous breast tumors.

**Companies:** Formosa Pharmaceuticals, Inc.
**Countries:** United States, Canada, Taiwan

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/22/tmt-newswire/pr-newswire/formosa-pharmaceuticals-announces-presentation-of-tsy-310-at-the-2026-asco-annual-meeting/2349736)

---

Canonical: https://newsio.io/n/044090b4-d01d-4662-b55d-43f91a87b12e/formosa-pharmaceuticals-inc
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works